Industry Payments for Vibegron and Prescribing Patterns Among Urologic Clinicians
Kayla Polcari, Max J. Hyman, Ted A. Skolarus, Anne E. Sales, David O. Meltzer, Parth K. Modi · 2023
Read Industry Payments for Vibegron and Prescribing Patterns Among Urologic Clinicians by Kayla Polcari, Max J. Hyman, Ted A. Skolarus, Anne E. Sales, David O. Meltzer, Parth K. Modi (2023) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/pmc-10739068.txt.
Description
Kayla Polcari and co-authors ask whether drug company payments to bladder specialists track with how much of a new, costly bladder drug they prescribe, in a 2023 study. The drug was the newest and priciest option for overactive bladder in its first year on the United States market. Payments are known to sway doctors' choices for pricey brands, but nurse practitioners and assistants also prescribe and receive payments.
Using public payment and Medicare prescribing records, the team compared clinicians who took payments tied to the drug with those who did not. The study design lets readers see whether paid clinicians prescribed the drug more often and in larger shares. The work adds to debate on how industry money shapes everyday prescribing.
Catalog record
| CREATOR | Kayla Polcari, Max J. Hyman, Ted A. Skolarus, Anne E. Sales, David O. Meltzer, Parth K. Modi |
|---|---|
| YEAR | 2023 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 9 KB |
| VERSION | 1.0 |
| LICENSE | CC BY 4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |